We have previously demonstrated that combined treatment with a CDK4/6 inhibitor and an MDM2 inhibitor suppresses the growth of melanoma patient-derived xenografts and that knockdown of CDK2 overcomes resistance to CDK4/6 inhibition (17). Here, MDM2 is linked to melanoma.